HPL in potential minimally invasive cell therapy
A new publication from Kouroupis et al. published in CYTOTHERAPY in July 2020 found out that infrapatellar fat pad (IFP)-mesenchymal stem cells (MSCs) manufactured with human Platelet Lysate (hPL) show enhanced immunomodulatory properties. Findings have potential for a minimally invasive cell therapy for joint disease The authors even
